Uta Oelschlaegel

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke et al. · Leukemia · 2011 · 395 citations · Full text

Medicine, Hematology, Pharmacology +17

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

Christoph Röllig, Christian Thiede, Martin Gramatzki et al. · Blood · 2010 · 177 citations · Full text

Medicine, Hematology, Oncology +15

PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells

Frank Pistrosch, Kay Herbrig, Uta Oelschlaegel et al. · Atherosclerosis · 2005 · 156 citations

Life Sciences, Cell Biology, Pharmacology +14

Cytarabine Dose of 36 g/m² Compared With 12 g/m² Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

Markus Schaich, Christoph Röllig, Silke Soucek et al. · Journal of Clinical Oncology · 2011 · 102 citations · Full text

Medicine, Oncology, Pharmacology +15

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Theresia M. Westers, Eline M.P. Cremers, Uta Oelschlaegel et al. · Haematologica · 2016 · 100 citations · Full text

Medicine, Hematology, Pathology +17